Rimon Therapeutics (Toronto) is researching applications for Theramers™, a family of medical polymers

that have biological activity and can potentially be used in scaffolds, beads and coatings. Theramers

work on contact by disrupting the bacterial cell membrane and inhibiting the activity of MMPs.

The company gave an oral presentation of a 32-subject clinical trial on MI-Sorb, a Theramer-based

dressing, used on ulcerated wounds which validated its efficacy.

Other applications of its core technology are Angiogenic Theramer™ for inducing the growth of new

blood vessels in wounds or other ischemic tissue; AM Theramer™, a thermoplastic material that kills gram

positive and gram negative bacteria without harming mammalian cells; and ThermaGel, a polymer that

changes from a liquid to a strong gel at body temperature.